Study details
Enrolling now
AlloNK® Trial
Artiva Biotherapeutics, Inc.
NCT IDNCT06991114ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
90
Study length
about 3.6 years
Ages
18+
Locations
16 sites in AL, AZ, CA +6
About this study
Researchers are testing the safety and effectiveness of AlloNK®, a non-genetically modified allogeneic NK cell therapy, combined with rituximab in people with relapsing forms of B-cell dependent rheumatologic diseases. The trial will last for about 1302 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Allogeneic NK Cells
PhasePhase 2
Primary goalSafety
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low6%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Safety
Body systems
Immune